DEVELOPMENT AND VALIDATION OF NOVEL RP-HPLC-DAD METHOD FOR QUANTIFICATION OF LAPATINIB DITOSYLATE IN NEWER NANO-LIPOSOME FORMULATION: A QUALITY BY DESIGN (QBD) APPROACH

PRIYANKA SONAR; KARIMUNNISA SHAIKH; SUNIL HARER

doi:10.22159/ijap.2022v14i6.45750

Authors

PRIYANKA SONAR Department of Pharmaceutics, PES’s, Modern College of Pharmacy, Nigdi, Pune, Maharashtra, India https://orcid.org/0000-0003-4323-7537
KARIMUNNISA SHAIKH Department of Pharmaceutics, PES’s, Modern College of Pharmacy, Nigdi, Pune, Maharashtra, India https://orcid.org/0000-0001-8315-6200
SUNIL HARER Department of Pharmaceutical Chemistry, Dattakala College of Pharmacy, Pune, Maharashtra, India https://orcid.org/0000-0003-2916-727X

DOI:

https://doi.org/10.22159/ijap.2022v14i6.45750

Keywords:

RP-HPLC, Quality by Design, Validation, Lapatinib ditosylate, Liposome

Abstract

Objective: The current study entails quality by design (QbD) enabled the development of a simple, rapid, sensitive, and cost-effective RP-HPLC method for estimation of Lapatinib ditosylate (LPT) in a newly prepared nano-liposomal formulation which has not been reported earlier.

Methods: The chromatographic factors were screened using a fractional factorial design. A central composite design was employed as a response surface methodology. Mobile phase ratio, flow rate, and wavelength were identified as critical method parameters. To minimize retention time, peak area and theoretical plates were employed as critical analytical attributes. A novel nano-liposomal formulation of LPT was prepared by the film hydration method.

Results: The optimized chromatographic condition was obtained at a mobile phase composition of methanol and 0.05% v/v o-phosphoric acid in water (81:19 v/v), flow rate 0.7 ml/min, and peak detected at wavelength 261 nm using DAD detector. The retention time for Lapatinib was 3.702 min. The developed method was validated as per ICH guidelines ICH Q2 (R1). Linearity (R2= 0.999) was observed in the range of 10-50μg/ml. The limit of detection and limit of quantitation was found to be 0.6309μg/ml and 1.9120μg/ml, respectively. LPT containing liposome formulation assay was found to be 99.03% and %RSD was less than 1%.

Conclusion: The newly developed RP-HPLC method applying the QbD approach was found to be simple, specific, precise, accurate, linear, and rugged, with good recovery of LPT in the nano-liposome formulation in a cost-effective manner. Hence it can be employed for the quantification of LPT in bulk and pharmaceutical formulations.

Downloads

Download data is not yet available.

References

Beg S, Sharma G, Katare OP, Lohan S, Singh B. Development and validation of a stability-indicating liquid chromatographic method for estimating olmesartan medoxomil using quality by design. J Chromatogr Sci. 2015;53(7):1048-59. doi: 10.1093/chromsci/bmu165, PMID 25583970.

The International Conference on Harmonization ICH technical requirements for registration of pharmaceuticals for human use on pharmaceutical. Development. 2009;Q8(R2). https://database.ich.org/sites/default/files/Q8%2 8R2%29%20Guideline.pdf

The international Conference on Harmonization ICH technical requirements for registration of pharmaceuticals for human use on quality. Risk Manag. 2005;Q9. https://database.ich.org/sites/default/files/Q9%20Guideline.pdf.

The international Conference on Harmonization ICH technical requirements for registration of pharmaceuticals for human use on pharmaceutical quality system; 2008. Available from: https://database.ich.org/sites/default/files/Q10%20Guideline.pdf.

Borman P, Nethercote P, Chatfield M, Thompson D, Truman K. The application of quality by design to analytical methods. Pharm Technol. 2007;31:142-52.

Schweitzer M, Pohl M, Hanna BM, Nethercote P, Borman P, Hansen G. Implications and opportunities of applying QbD principles to analytical measurements. Pharm Technol. 2010;34:52-9.

Galen WE. Analytical instrumentation handbook. 2nd ed. New York: Marcel Dekker Inc; 2004.

Snyder L, Kirkland J, Glajch L. New York: John Wiley & Sons Inc. 2nd ed. Practical HPLC method development; 2014. p. 859. doi: 10.1002/978111.

Bossunia MTI, Urmi KF, Shaha CK. Quality-by-design approach to stability indicating RP-HPLC analytical method development for estimation of canagliflozin API and its validation. PHME. 2017;8(2):92-101. doi: 10.5530/phm.2017.8.15.

Sandhu PS, Beg S, Katare OP, Singh B. QbD-driven development and validation of a HPLC method for estimation of tamoxifen citrate with improved performance. J Chromatogr Sci. 2016;54(8):1373-84. doi: 10.1093/chromsci/bmw090.

Mondal S, Biswal S, Acharya T, Mondal P, Bhar K. Determination of lapatinib in bulk and tablet dosage form using ultraviolet spectrophotometric and RP-HPLC analytical methods. Int J Pharm Investig. 2021;11(2):208-13. doi: 10.5530/ijpi.2021.2.37.

Kumar KK, Nagoji KE, Nadh RV. A validated RP-HPLC method for the estimation of lapatinib in tablet dosage form using gemcitabine hydrochloride as an internal standard. Indian J Pharm Sci. 2012;74(6):580-3. doi: 10.4103/0250-474X.110621, PMID 23798787.

Haribabu B, BalaMurali KK, Rama KP. Development and validation of HPLC method for the estimation of lapatinib in bulk drugs and pharmaceutical formulations. Int J Res Rev Pharm Appl Sci. 2011;1:207-14.

Reehana SK, Sujana K. LC-MS/MS characterization of forced degradation products of tucatinib, a novel tyrosine kinase inhibitor: development and validation of RP-HPLC method. Int J Appl Pharm. 2022;14(1):58-66. doi: 10.22159/ijap.2022v14i1.43252.

Palnati N, Kotapati N, Vaidyanathan G. Liquid chromatography–mass spectrometry/mass spectrometry method for the determination of lapatinib in rat plasma: application to pharmacokinetic studies in wistar rats. Asian J Pharm Clin Res. 2021;14(2):74-7. doi: 10.22159/ajpcr.2021.v14i2.39660.

Bai F, Freeman BB 3rd, Fraga CH, Fouladi M, Stewart CF. Determination of lapatinib (GW572016) in human plasma by liquid chromatography electrospray tandem mass spectrometry (LC-ESI-MS/MS). J Chromatogr B Anal Technol Biomed Life Sci. 2006;831(1-2):169-75. doi: 10.1016/j.jchromb.2005.11.044, PMID 16364699.

Haouala A, Zanolari B, Rochat B, Montemurro M, Zaman K, Duchosal MA. Therapeutic drug monitoring of the new targeted anticancer agents imatinib, nilotinib, dasatinib, sunitinib, sorafenib and lapatinib by LC tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2009;877(22):1982-96. doi: 10.1016/j.jchromb.2009.04.045, PMID 19505856.

Sandra R, Gillian McM, Martin C, Robert OC. Development and application of novel analytical methods for molecularly targeted cancer therapeutics. J Chromatogr B. 2009;877:3982-90.

Götze L, Hegele A, Metzelder SK, Renz H, Nockher WA. Development and clinical application of a LC-MS/MS method for simultaneous determination of various tyrosine kinase inhibitors in human plasma. Clin Chim Acta. 2012;413(1-2):143-9. doi: 10.1016/j.cca.2011.09.012, PMID 21945732.

Couchman L, Birch M, Ireland R, Corrigan A, Wickramasinghe S, Josephs D. An automated method for the measurement of a range of tyrosine kinase inhibitors in human plasma or serum using turbulent flow liquid chromatography-tandem mass spectrometry. Anal Bioanal Chem. 2012;403(6):1685-95. doi: 10.1007/s00216-012-5970-2, PMID 22526649.

Bouchet S, Chauzit E, Ducint D, Castaing N, Canal Raffin M, Moore N. Simultaneous determination of nine tyrosine kinase inhibitors by 96-well solid-phase extraction and ultra performance LC/MS-MS. Clin Chim Acta. 2011;412(11-12):1060-7. doi: 10.1016/j.cca.2011.02.023, PMID 21345336.

Rakic T, Kasagic Vujanovic I, Jovanovic M, Jancic Stojanovic B, Ivanovic D. Comparison of full factorial design, central composite design, and box-behnken design in chromatographic method development for the determination of fluconazole and its impurities. Anal Lett. 2014;47(8):1334-47. doi: 10.1080/00032719.2013.867503.

Bezerra MA, Santelli RE, Oliveira EP, Villar LS, Escaleira LA. Response surface methodology (RSM) as a tool for optimization in analytical chemistry. Talanta. 2008;76(5):965-77. doi: 10.1016/j.talanta.2008.05.019, PMID 18761143.

Narahari P, Vijayaraj S, Lathasri K, Archana D, Rajavel P. Chemometric approach to develop and validate RP-HPLC method for estimation of erlotinib hydrochloride in nano structured lipid carriers. Curr Pharm Anal. 2019;15:1-6.

Ferreira SLC, Caires AO, Tda BS, Lima AMDS, Silva LOB, dos Santos WNL. Robustness evaluation in analytical methods optimized using experimental designs. Microchemical Journal. 2017;131:163-9. doi: 10.1016/j.microc.2016.12.004.

Shrivastava R, Trivedi S, Singh PK, Asif M, Chourasia MK, Khanna A. Design and development of pegylated liposomal formulation of HER2 blocker Lapatinib for enhanced anticancer activity and diminished cardiotoxicity. Biochem Biophys Res Commun. 2018;503(2):677-83. doi: 10.1016/j.bbrc.2018.06.060, PMID 29908185.

Charumathy A, Ubaidulla U, Sinha P, Rathnam G. Recent update on liposome-based drug delivery system. Int J Curr Pharm Sci. 2022;14(3):22-7. doi: 10.22159/ijcpr.2022v14i3.1991.

Kumar KK, Nagoji KEV, Nadh RV. A validated RP-HPLC method for the estimation of Lapatinib in tablet dosage form using gemcitabine hydrochloride as an internal standard. Indian J Pharm Sci. 2012;74(6):580-3. doi: 10.4103/0250-474X.110621, PMID 23798787.

Singh B, Kumar R, Ahuja N. Optimizing drug delivery systems using systematic “Design of Experiments.” Part I: fundamental aspects. Crit Rev Ther Drug Carrier Syst. 2005;22(1):27-105. doi: 10.1615/CritRevTherDrugCarrierSyst.v22.i1.20.

Beg S, Chaudhary V, Sharma G, Garg B, Panda SS, Singh B. QbD‐oriented development and validation of a bioanalytical method for nevirapine with enhanced liquid–liquid extraction and chromatographic separation. Biomed Chromatogr. 2016;30(6):818-28. doi: 10.1002/bmc.3613, PMID 26352459.

Merey HA, Galal MM, Salem MY, Abdel-Moety EM. Novel stability indicating methods for the determination of certain synthetic estrogen level modifiers. Bull Fac Pharm Cairo Univ. 2013;51(1):69-79. doi: 10.1016/j.bfopcu.2012.11.001.

Bhoop BS, Beg S, Raza K. Developing ”optimized” drug products employing ”designed” experiments. Chemical Industry Digest. 2013;23:70-6.

Kaur R, Saini S, Sharma T, Katare OP, Kaushik A, Singh B. Implementation of analytical quality-by-design for developing a robust HPLC method for quantitative estimation of voriconazole: application in drug formulations. Anal Chem Lett. 2021;11(2):168-86. doi: 10.1080/22297928.2021.1888793.

Sandhu PS, Beg S, Katare OP, Singh B. QbD-driven development and validation of a HPLC method for estimation of tamoxifen citrate with improved performance. J Chromatogr Sci. 2016;54(8):1373-84. doi: 10.1093/chromsci/bmw090.

IHT Guideline. Validation of analytical procedures: text and methodology Q2 (R1); 2005. http://www. Ich.org/cache/compo/ 363-272-1 html.

Shimek JL, Rao NGS, Khalil SKW. High performance liquid chromatographic analysis of tolmetin, indomethacin and sulindac in plasma. J Liq Chromatogr. 1981;4(11):1987-2013. doi: 10.1080/01483918108067556.

Muller IB, Windberg CN. Validation of an HPLC method for quantitation of MDMA in tablets. J Chromatogr Sci. 2005;43(8):434-37. doi: 10.1093/chromsci/43.8.434, PMID 16212786.

Vander Heyden Y, Nijhuis A, Smeyers Verbeke J, Vandeginste BG, Massart DL. Guidance for robustness/ruggedness tests in method validation. J Pharm Biomed Anal. 2001;24(5-6):723-53. doi: 10.1016/s0731-7085(00)00529-x, PMID 11248467.

Shabir GA. Validation of high-performance liquid chromatography methods for pharmaceutical analysis. Understanding the differences and similarities between validation requirements of the US Food and Drug Administration, the US Pharmacopeia and the International Conference on Harmonization. J Chromatogr A. 2003;987(1-2):57-66. doi: 10.1016/s0021-9673(02)01536-4, PMID 12613797.

Saadat E, Dehghan Kelishady P, Ravar F, Kobarfard F, Dorkoosh FA. Development and validation of rapid stability-indicating RP-HPLC-DAD method for the quantification of lapatinib and mass spectrometry analysis of degraded products. J Chromatogr Sci. 2015;53(6):932-9. doi: 10.1093/chromsci/bmu150, PMID 25491314.

Panda SS, Bera RKVV, Behera AK, Beg S. Chemometrics-assisted development of a liquid chromatography method for estimation of lapatinib in tablets: A case study on a novel quality concept. Sep Sci Plus. 2020;3(1-2):12-21. doi: 10.1002/sscp.201900096.

Saadat E, Ravar F, Dehghankelishadi P, Dorkoosh FA. Development and validation of a rapid RP-HPLC-DAD analysis method for the simultaneous quantitation of paclitaxel and lapatinib in a polymeric micelle formulation. Sci Pharm. 2016;84(2):333-45. doi: 10.3797/scipharm.1507-03, PMID 27222608.

Alrobaian M, Panda SS, Almalki WH, Afzal O, Kazmi I, Alossaimi MA. Development and validation of chemometrics-assisted green UPLC-MS/MS bioanalytical method for simultaneous estimation of capecitabine and lapatinib in rat plasma. J Chromatogr Sci. 2022;60(6):559-70. doi: 10.1093/chromsci/bmab094, PMID 34318311.